You are in: eMedicine Specialties > Emergency Medicine > CARDIOVASCULAR Thoracic Outlet SyndromeArticle Last Updated: Feb 4, 2008AUTHOR AND EDITOR INFORMATIONAuthor: Andrew K Chang, MD, Assistant Professor, Department of Emergency Medicine, Albert Einstein College of Medicine, Montefiore Medical Center Andrew K Chang is a member of the following medical societies: American Academy of Emergency Medicine, American Academy of Neurology, American College of Emergency Physicians, and Society for Academic Emergency Medicine Coauthor(s): J Stephen Bohan, MD, FACP, FACEP, Director, Observation Medicine, Department of Emergency Medicine, Clinical Director, Harvard Medical School, Brigham and Women's Hospital Editors: Richard S Krause, MD, Clinical Assistant Professor, Residency Program Director, Department of Emergency Medicine, State University of New York at Buffalo School of Medicine; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; David Eitel, MD, MBA, Associate Professor, Department of Emergency Medicine, York Hospital; John D Halamka, MD, MS, Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center; Charles V Pollack, Jr, MD, MA, FACEP, Professor, Department of Emergency Medicine, University of Pennsylvania College of Medicine; Chairman, Department of Emergency Medicine, Pennsylvania Hospital Author and Editor Disclosure Synonyms and related keywords: TOS, vascular thoracic outlet syndrome, vascular TOS, neurologic thoracic outlet syndrome, neurologic TOS, arterial thoracic outlet syndrome, arterial TOS, venous thoracic outlet syndrome, venous TOS, compression of neurovascular structures, pain in the ulnar nerve distribution, paresthesias in the ulnar nerve distribution, cold intolerance, elevated arm stress test, EAST, supraclavicular tenderness, Gilliatt-Sumner hand, edema of the upper extremity, cyanosis of theupper extremity, distended superficial veins of the shoulder, distended superficial veins of the chest, cervical ribs, scalene triangle, congenital fibromuscular bands, elongated transverse process of C7, motor vehicle accident hyperextension injury, effort vein thrombosis, neurovascular entrapment INTRODUCTIONBackgroundThoracic outlet syndrome (TOS) is a broad term that refers to compression of the neurovascular structures in the area just above the first rib and behind the clavicle. It represents a constellation of symptoms. The cause, diagnosis, and treatment are controversial. The brachial plexus (95%), subclavian vein (4%), and subclavian artery (1%) are affected. Most presentations to the emergency department (ED) are nonemergent and require only symptomatic treatment and referral. PathophysiologyThe brachial plexus trunks and subclavian vessels are subject to compression or irritation as they course through 3 narrow passageways from the base of the neck toward the axilla and the proximal arm. The most important of these passageways is the interscalene triangle, which is also the most proximal. This triangle is bordered by the anterior scalene muscle anteriorly, the middle scalene muscle posteriorly, and the medial surface of the first rib inferiorly. This area may be small at rest and may become even smaller with certain provocative maneuvers. Anomalous structures, such as fibrous bands, cervical ribs, and anomalous muscles, may constrict this triangle further. Repetitive trauma to the plexus elements, particularly the lower trunk and C8-T1 spinal nerves, is thought to play an important role in the pathogenesis of TOS. The second passageway is the costoclavicular triangle, which is bordered anteriorly by the middle third of the clavicle, posteromedially by the first rib, and posterolaterally by the upper border of the scapula. The last passageway is the subcoracoid space beneath the coracoid process just deep to the pectoralis minor tendon. FrequencyUnited StatesBecause no objective confirmatory test is available for TOS, there is much disagreement with regards to its true incidence, with reported figures ranging from 3-80 cases per 1000 people. SexThe sex ratio varies depending on the type of TOS (eg, neurologic, venous, arterial). Overall, the entity is approximately 3 times more common in women than in men.
AgeThe onset of symptoms usually occurs in persons aged 20-50 years. CLINICALHistory
PhysicalIn most cases, the physical examination findings are completely normal. Other times, the examination is difficult because the patient may guard the extremity and exhibit giveaway-type weakness. The sensory examination is often unreliable.
CausesThe 3 major causes of TOS are anatomic, trauma/repetitive activities, and neurovascular entrapment at the costoclavicular space.
DIFFERENTIALSAcute Coronary Syndrome Carpal Tunnel Syndrome Multiple Sclerosis Neoplasms, Spinal Cord Rotator Cuff Injuries Spinal Cord Injuries Thrombophlebitis, Superficial
|
| Drug Name | Heparin |
|---|---|
| Description | Augments activity of antithrombin III and prevents conversion of fibrinogen to fibrin. Does not actively lyse but is able to inhibit further thrombogenesis. Prevents re-accumulation of clot after spontaneous fibrinolysis. |
| Adult Dose | Loading dose: 80 U/kg Maintenance infusion: 18 U/kg/h Alternatively, start with 50 U/kg/h, followed by continuous infusion of 15-25 U/kg/h; increase by 5 U/kg/h q4h prn using aPTT results |
| Pediatric Dose | Loading dose: 50 U/kg/h Maintenance infusion: 15-25 U/kg/h Increase dose by 2-4 U/kg/h q6-8h prn using aPTT results |
| Contraindications | Documented hypersensitivity; subacute bacterial endocarditis; active bleeding; history of heparin-induced thrombocytopenia |
| Interactions | Digoxin, nicotine, tetracycline, and antihistamines may decrease effects; NSAIDs, aspirin, dextran, dipyridamole, and hydroxychloroquine may increase toxicity |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | In neonates, preservative-free heparin is recommended to avoid possible toxicity (ie, gasping syndrome) by benzyl alcohol, which is used as preservative; caution in severe hypotension and shock |
| Drug Name | Warfarin (Coumadin) |
|---|---|
| Description | Interferes with hepatic synthesis of vitamin K–dependent coagulation factors. Used for prophylaxis and treatment of venous thrombosis, pulmonary embolism, and thromboembolic disorders. Tailor dose to maintain INR in range of 2-3. Infants may require doses at, or near, high end of range. |
| Adult Dose | 5-15 mg/d PO qd for 2-5 d; adjust dose according to desired INR |
| Pediatric Dose | 0.05-0.34 mg/kg/d PO; adjust dose according to desired INR |
| Contraindications | Documented hypersensitivity; severe liver or kidney disease; open wounds; GI ulcers |
| Interactions | Drugs that may decrease anticoagulant effects include griseofulvin, carbamazepine, glutethimide, estrogens, nafcillin, phenytoin, rifampin, barbiturates, cholestyramine, colestipol, vitamin K, spironolactone, oral contraceptives, and sucralfate Medications that may increase anticoagulant effects include oral antibiotics, phenylbutazone, salicylates, sulfonamides, chloral hydrate, clofibrate, diazoxide, anabolic steroids, ketoconazole, ethacrynic acid, miconazole, nalidixic acid, sulfonylureas, allopurinol, chloramphenicol, cimetidine, disulfiram, metronidazole, phenylbutazone, phenytoin, propoxyphene, sulfonamides, gemfibrozil, acetaminophen, and sulindac |
| Pregnancy | D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus |
| Precautions | Do not switch brands after achieving therapeutic response; caution in active tuberculosis or diabetes; patients with protein C or S deficiency are at risk of developing skin necrosis |
If analgesic treatment is ineffective, a short, monitored course of TCAs can be helpful if the time course and symptoms suggest a protracted pain syndrome. The primary care physician or neurologist (not the ED physician) should be the one to prescribe such therapy.
| Drug Name | Doxepin (Sinequan, Adapin, Zonalon) |
|---|---|
| Description | Inhibits histamine and acetylcholine activity and has proven useful in treatment of various forms of depression associated with chronic and neuropathic pain. |
| Adult Dose | 30-150 mg/d PO hs or in 2-3 divided doses; gradually increase dose to 300 mg/d prn |
| Pediatric Dose | <12 years: Not recommended >12 years: 25-50 mg/d PO hs or bid/tid and increase gradually to 100 mg/d |
| Contraindications | Documented hypersensitivity; urinary retention; acute recovery phase following myocardial infarction; glaucoma |
| Interactions | Decreases antihypertensive effects of clonidine but increases effects of sympathomimetics and benzodiazepines; effects increase with phenytoin, carbamazepine, and barbiturates |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Caution in cardiovascular disease, conduction disturbances, seizure disorders, urinary retention, and hyperthyroidism and in patients receiving thyroid replacement; perform baseline and periodic leukocyte and differential counts and liver function tests; discontinue if evidence of neutropenia |
Pain control is essential to quality patient care. It ensures patient comfort, promotes pulmonary toilet, and enables physical therapy regimens. Many analgesics have sedating properties, which are beneficial for patients who have sustained injuries.
| Drug Name | Acetaminophen (Tylenol, Aspirin Free Anacin, Feverall) |
|---|---|
| Description | DOC for pain in patients with documented hypersensitivity to aspirin or NSAIDs, with upper GI disease, or who are taking oral anticoagulants. |
| Adult Dose | 325-650 mg PO q4-6h or 1000 mg tid/qid; not to exceed 4 g/d |
| Pediatric Dose | <12 years: 10-15 mg/kg/dose PO q4-6h prn; not to exceed 2.6 g/d >12 years: 325-650 mg PO q4h; not to exceed 5 doses in 24 h |
| Contraindications | Documented hypersensitivity; known G-6-PD deficiency |
| Interactions | Rifampin can reduce analgesic effects of acetaminophen; coadministration with barbiturates, carbamazepine, hydantoins, and isoniazid may increase hepatotoxicity |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Hepatotoxicity possible in chronic alcoholics following various dose levels; severe or recurrent pain or high or continued fever may indicate serious illness; acetaminophen contained in many OTC products, and combined use with these products may result in cumulative acetaminophen doses exceeding recommended maximum dose |
| Drug Name | Acetaminophen and codeine (Tylenol with codeine) |
|---|---|
| Description | Drug combination indicated for treatment of mild to moderately severe pain. |
| Adult Dose | 30-60 mg/dose based on codeine content PO q4-6h or 1-2 tab q4h; not to exceed 12 tabs in 24h |
| Pediatric Dose | 0.5-1 mg/kg/dose based on codeine PO q4-6h; 10-15 mg/kg/dose based on acetaminophen content; not to exceed 2.6 g/d of acetaminophen |
| Contraindications | Documented hypersensitivity |
| Interactions | CNS depressants or tricyclic antidepressants increase toxicity |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Caution in patients dependent on opiates, since this substitution may result in acute opiate-withdrawal symptoms; caution in severe renal or hepatic dysfunction |
| Drug Name | Ibuprofen (Motrin, Ibuprin, Nuprin, Advil) |
|---|---|
| Description | DOC for patients with mild to moderately severe pain. Inhibits inflammatory reactions and pain by decreasing prostaglandin synthesis. |
| Adult Dose | 200-400 mg PO q4-6h while symptoms persist; not to exceed 3.2 g/d |
| Pediatric Dose | <6 months: Not established 6 months to 12 years: 30-70 mg/kg/d divided PO tid/qid; not to exceed 2.4 g/d >12 years: Administer as in adults |
| Contraindications | Documented hypersensitivity; peptic ulcer disease; recent GI bleeding or perforation; renal insufficiency; high risk of bleeding |
| Interactions | Aspirin increases risk of inducing serious NSAID-related adverse effects; probenecid may increase concentrations and, possibly, toxicity; may decrease effects of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; may increase PT in patients taking anticoagulants—monitor PT closely and instruct patients to watch for signs of bleeding; may increase risk of methotrexate toxicity; may increase phenytoin levels |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus |
| Precautions | Caution in congestive heart failure, hypertension, and decreased renal and hepatic function; caution in coagulation abnormalities or during anticoagulant therapy |
Thoracic Outlet Syndrome excerpt
Article Last Updated: Feb 4, 2008